Return on Equity (ROE): 23.25%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 23.25% is 66% above its 5-year average of 14.02%, around the middle of its 5-year range (0.97%–34.52%).
As of Thursday, June 25, 2026. 8.52% below its 12-month average of 25.41%.
PODD Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
PODD Average Return on Equity (ROE) Chart
PODD Current vs Average Return on Equity (ROE) Chart
PODD Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
23.25%
RETURN ON EQUITY (ROE) AVG TTM
25.41%
RETURN ON EQUITY (ROE) AVG 3Y
19.99%
RETURN ON EQUITY (ROE) AVG 5Y
14.02%
RETURN ON EQUITY (ROE) AVG 10Y
-16.15%
RETURN ON EQUITY (ROE) AVG 15Y
-23.27%
RETURN ON EQUITY (ROE) AVG 20Y
-35.27%
CURRENT VS TTM AVG
-8.52%
CURRENT VS 3Y AVG
+16.31%
CURRENT VS 5Y AVG
+65.85%
CURRENT VS 10Y AVG
+243.98%
CURRENT VS 15Y AVG
+199.91%
CURRENT VS 20Y AVG
+165.92%
PODD Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 23.25% | 25.41% | 19.99% | 14.02% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Baxter International Inc. (BAX)vs › | $10.87B | -18.17% | -12.46% | -8.76% | -1.37% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | -6.28% | -2.13% | 6.32% | 9.65% |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 12.09% | 11.88% | 12.69% | 13.50% |
| Revvity, Inc. (RVTY)vs › | $11.78B | 3.35% | 3.59% | 3.35% | 7.68% |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 10.36% | 10.54% | 10.84% | 19.93% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 2.46% | -8.94% | -15.72% | 1.14% |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | -2.37% | -21.41% | -36.14% | -25.75% |
| Solventum Corporation (SOLV)vs › | $13.09B | 28.82% | 23.51% | 17.50% | 13.68% |
Return Analysis
ROE
23.3%
ROA
10.1%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Insulet Corp. (PODD)?
- The return on equity (ROE) for PODD stock is 23.25%.
- Is Insulet Corp.'s return on equity (ROE) high or low?
- The return on equity (ROE) of 23.25% is 66% above its 5-year average of 14.02%, around the middle of its 5-year range (0.97%–34.52%).
- What is the TTM average return on equity (ROE) for Insulet Corp. (PODD)?
- The TTM average return on equity (ROE) for PODD stock is 25.41%.
- What is the 3Y average return on equity (ROE) for Insulet Corp. (PODD)?
- The 3Y average return on equity (ROE) for PODD stock is 19.99%.
- What is the 5Y average return on equity (ROE) for Insulet Corp. (PODD)?
- The 5Y average return on equity (ROE) for PODD stock is 14.02%.
- What is the 10Y average return on equity (ROE) for Insulet Corp. (PODD)?
- The 10Y average return on equity (ROE) for PODD stock is -16.15%.
- What is the 15Y average return on equity (ROE) for Insulet Corp. (PODD)?
- The 15Y average return on equity (ROE) for PODD stock is -23.27%.
- What is the 20Y average return on equity (ROE) for Insulet Corp. (PODD)?
- The 20Y average return on equity (ROE) for PODD stock is -35.27%.
PODD Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 16.31% |
| 2024-12-31 | 34.52% |
| 2023-12-31 | 28.16% |
| 2022-12-31 | 0.97% |
| 2021-12-31 | 3.02% |
| 2020-12-31 | 1.13% |
| 2019-12-31 | 15.28% |
| 2018-12-31 | 1.55% |
| 2017-12-31 | -16.93% |
| 2016-12-31 | -45.73% |
| 2015-12-31 | -215.91% |
| 2014-12-31 | -61.43% |
| 2013-12-31 | -36.10% |
| 2012-12-31 | -117.41% |
| 2011-12-31 | -80.07% |
| 2010-12-31 | -92.34% |
| 2009-12-31 | -150.48% |
| 2008-12-31 | -2171.06% |
| 2007-12-31 | -58.02% |
| 2006-12-31 | 35.33% |
| 2005-12-31 | 32.74% |
| 2004-12-31 | 31.05% |
| 2003-12-31 | 38.96% |
| 2002-12-31 | 67.44% |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy